Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome
The specific hypotheses are: Gluten supplementation for four weeks increases small intestinal permeability and accelerates colonic transit in patients with irritable bowel syndrome with diarrhea (IBS-D) or functional diarrhea…
- Trial name
- NCT01094041
- Testing
- Gluten free diet, Gluten rich diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
IBS, Diarrhea Predominant
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase III clinical trial. Its purpose is to evaluate the efficacy and safety of Changji'an Capsules in subjects with diarrhea-predominant…
- Trial name
- NCT07610434
- Testing
- Chang Ji'an capsule, Chang Ji'an capsule mimic
- Where
- 29 sites in China
- Volunteers
- 636 people
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
- Trial name
- NCT00399438
- Testing
- BMS-562086
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Diarrhea-predominant Irritable Bowel Syndrome, Functional Diarrhea
Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial
This trial is to assess the effectiveness of three types of acupuncture for patients with functional diarrhea comparing to a positive drug control.
- Trial name
- NCT01350570
- Testing
- acupuncture, acupuncture group2, acupuncture group3
- Where
- China
- Volunteers
- 449 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial
Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Chronic Diarrhea
- Trial name
- rTMS (NCT07581756)
- Testing
- rTMS group
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Irritable Bowel Syndrome
Mediterranean Diet and the Gut Microbiome
This study will evaluate the impact of a Mediterranean-style diet on microbiome diversity compared to a typical American diet. The study will observe the microbiome composition comparisons in healthy volunteers as well as in…
- Trial name
- NCT03269032
- Testing
- American Diet, Mediterranean-style Diet
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Efficacy of Rifaximin With NAC in IBS-D
The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D).
- Trial name
- NCT06727422
- Testing
- rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Mark Pimentel, MD
Diarrhea- Predominant Irritable Bowel Syndrome, Quality of Life
Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome
The aim of this study is to evaluate the effects of Mesalamine and Amitriptyline drugs on the Quality of Life and Symptom Severity Scale in patients with Diarrhea- Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- NCT02190526
- Testing
- Mesalazine(asacol 800 mg), Amitriptyline
- Where
- Iran
- Sponsor
- Tehran University of Medical Sciences
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc
Irritable Bowel Syndrome
Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
The purpose of this study is to evaluate the efficacy as well as safety of rifaximin combined fecal microbiota transplantation(Gut microbiota reconstruction) in the treatment of IBS-D.
- Trial name
- NCT02651740
- Testing
- Rifaximin, Fecal microbiota transplantation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Zhongshan Hospital
Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome
To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome
To evaluate whether there is clinical improvement through the scales (Bristol, IBS severity score, and IBS quality of life) in women with irritable bowel syndrome after administration of SC-FOS (short-chain…
- Conditions
- Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome, Constipation-predominant Irritable Bowel Syndrome
- Trial name
- NCT05941650
- Testing
- Short Chain Fructooligosaccharides, Corn Starch
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Chihuahua
Diarrhea-predominant Irritable Bowel Syndrome
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01870895
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) carries a high prevalence worldwide and imposes substantial economic burden on patients, healthcare systems and society.
- Trial name
- NCT03557788
- Testing
- Rifaximin Oral Tablet
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Irritable Bowel Syndrome with Diarrhea, Purine Metabolism Disorder
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method.
- Trial name
- NCT06612411
- Testing
- B. subtilis, Dead B. subtilis
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Jinling Hospital, China